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sion diagnosis, while SF-12 PCS and K6 were not associated (p  0.05). CONCLU-
SIONS: Routinely collected patient reported health status may be useful to providers 
and payers as an aid in diagnosing depression in CMD patients.
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DIFFICULT TO SWALLOW: PATIENT PREFERENCES REGARDING
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OBJECTIVES: Characteristics such as tablet size and ease-of-swallowing can affect
patients’ treatment preference, and could in turn affect patient medication compliance.
The objectives of this research were to determine the degree to which swallowing 
Valproate (VP) tablets is an issue, and the predictors of patient preference. METHODS:
We conducted a quantitative telephone survey of adults (n  400, q18 years old) who 
currently take (n  236) or previously took (n  164) VP tablets within the past 6 
months (125 mg, 250 mg, or 500 mg). After online recruitment and screening, eligible
participants completed a structured interview about medication use, perceived tablet
characteristics, and preferences. Multivariate regression analyses were conducted to
determine predictors of treatment preference. RESULTS: Respondents took an average 
2.5 (SD  1.23) VP tablets/day primarily to treat bipolar disorder (65.0%, n  260),
migraine (12.5%, n  50), or epilepsy (11.7%, n  47). More than half of the patients 
indicated that VP tablets were ‘uncomfortable to swallow’ (68.5%, n  274) and were 
‘very interested’ (65.8%, n  263) in medications that were easier to swallow. When 
choosing conceptually between taking their VP tablet once/day or an equally safe and 
effective but signiﬁ cantly smaller soft gel capsule twice/day, the majority (82.8%, n 
331) preferred the soft gel capsule. In the multivariate regression analysis, perceiving 
soft gel capsules to be easier to swallow (OR  73.54; 95% CI  15.01–360.40) and 
taking VP more frequently (OR  2.02; 95% CI  1.13–3.61) were signiﬁ cant predic-
tors of soft gel capsule treatment preference. CONCLUSIONS: In this survey-based 
study, users of VP would prefer a formulation that is easier to swallow. A higher 
patient preference may improve medication compliance. When choosing between 
medications with similar efﬁ cacy and safety, physicians can consider patient prefer-
ences for speciﬁ c tablet characteristics to optimize conditions for medication compli-
ance. Further research is warranted to examine compliance with medications that are 
easier to swallow.
PMH56
MEDICATION SATISFACTION IN SUBJECTS WITH SCHIZOPHRENIA 
TREATED WITH PALIPERIDONE ER AFTER SUBOPTIMAL RESPONSE TO 
ORAL RISPERIDONE
Canuso CM1, Grinspan A1, Merriman UE1, Damaraju C1, Dirani RG1, Kalali A2, Alphs L1
1Ortho-McNeil Janssen Scientiﬁ c Affairs, LLC, Titusville, NJ, USA, 2Quintiles, Inc, San Diego, 
CA, USA
OBJECTIVES: Medication satisfaction in subjects with schizophrenia may be related
to efﬁ cacy and long-term adherence. This study evaluated medication satisfaction after
treatment with paliperidone ER in subjects with a current suboptimal response to oral 
risperidone. METHODS: A 6-week, prospective, international, randomized, blinded-
initiation study. Inclusion criteria: schizophrenia per DSM-IV, treated with oral ris-
peridone (4 or 6 mg/day) at least 4 weeks prior to entry, PANSS score q4 on q3 items 
(tension, unusual thought content, delusions, hallucinatory behavior, excitement, gran-
diosity or suspiciousness/persecution) and dissatisfaction with current medication
(Treatment Satisfaction Questionnaire for Medication a3). Subjects randomized (1:1,
blinded) to paliperidone ER 6 mg/day (optional increase to 12 mg/day) either imme-
diately (6 weeks total) or delayed (continued risperidone for 2 weeks followed by 
paliperidone ER for 4 weeks). Primary end point for the overall group: change in
Medication Satisfaction Questionnaire (MSQ) (1  extremely dissatisﬁ ed to 7 
extremely satisﬁ ed) at week 6 end point. Additional end points: total PANSS and 
adverse events (AEs). Study ID: CR014347. RESULTS: 201 subjects were randomized 
to immediate (n  100) or delayed (n  101) initiation of paliperidone ER. For the 
overall group, mean (SD) MSQ score improved signiﬁ cantly from 2.7 (0.8) at baseline
to 5.1 (1.2) at end point (P  0.001). 82.7% of subjects were satisﬁ ed with their
medication at end point vs 3.7% at baseline. Mean (SD) PANSS total score improved 
from baseline to end point (¨C12.9 [13.1]; P  0.001). At week 2, a higher percentage
of subjects receiving paliperidone ER (immediate-initiation group) were satisﬁ ed with 
their medication compared with those still receiving risperidone (delayed-initiation 
group) (67.7% vs 45.3%; P  0.002). Most common AEs for overall group: insomnia 
(9.1%), constipation (7.6%), headache (7.6%) and somnolence (6.6%). CONCLU-
SIONS: Schizophrenia subjects suboptimally responsive to risperidone reported
improved medication satisfaction after 4 or 6 weeks of paliperidone ER.
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OBJECTIVES: Pharmacist’s dissatisfaction with the work caused by inadequate job 
demands, working environments and administrative requirements might lead to poor
performance, personnel’s burnout and turnover rate. However, the issues have been
scantly acknowledged. This study aimed to investigate the job satisfaction among 
hospital pharmacists in Taiwan. METHODS: Semi-structured interviews were con-
ducted with nine hospital pharmacists to explore the main concerns regarding job
satisfaction of the hospital pharmacists. Subsquently content analysis was performed 
to produce a questionnaire with 24 items covering dispensing workload, salary, beneﬁ t 
packages, education, and training. After the reliability and validity of the questionnaire
were tested, the revised questionnaire was distributed to all pharmacists in a medical 
center in Taipei. RESULTS: In total, 66.36% of 110 pharmacists responded to the
survey. Satisfaction scores ranged from 5 (extremely satisﬁ ed) to 1 (extremely dissatis-
ﬁ ed). The participants in this study were most satisﬁ ed with the working relationships 
with colleagues, the leadership of the head of pharmacy department, and the compe-
tency for providing patient consultations. The participants were most dissatisﬁ ed with
the heavy workload, night shifts, and the promotion system. The total mean satisfac-
tion score was 3.17 / 0.74, slightly higher than the mean value, without signiﬁ cant 
difference among varied groups of age, gender, salary, education levels and working 
years. However, longer working years seemed to signiﬁ cantly relate to higher satisfac-
tion level in salary. (F  3.17, P  0.01). CONCLUSIONS: It is recommended that 
decision makers need to consider the salary and shift systems to improve job satisfac-
tion of the pharmacists. Further survey is planned to distribute this questionnaire to 
a larger groups of pharmacists working in different levels of medical settings.
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OBJECTIVES: To evaluate use of an optional antipsychotic drug algorithm for treat-
ing inpatients with schizophrenia or schizoaffective disorder at a state psychiatric 
hospital. METHODS: Clinical outcomes were compared in patients whose treatment
followed a speciﬁ c antipsychotic drug algorithm versus those whose did not. First step
oral antipsychotic options in the algorithm were risperidone and ziprasidone. Docu-
mentation of a clinical rationale for use of a non-preferred drug was acceptable for
deviating from preferred choices. Antipsychotic polytherapy was the least preferred 
treatment. Steps for using injectable and non-preferred drugs were also speciﬁ ed.
Primary and secondary outcomes were length of hospitalization and patient achieve-
ment of “much improved” or “very much improved”, deﬁ ned by CGI-S score, respec-
tively. Prescribers reviewed patient record documentation to compare patients who
were adherent vs non-adherent to the algorithm. RESULTS: The total cohort was 401 
patients (263 algorithm adherent and 138 non-adherent). Three algorithm adherent 
patients were dropped due to a CGI-S score of 7 therefore, 260 were used in the 
analysis. Sixty-seven percent were male. The mean age was 39. The median number
of past hospitalizations was 2. The modal rating of severity on the Clinical Global 
Impression—Severity was 5, markedly ill. There were no signiﬁ cant differences 
between groups on gender, number of past hospitalizations and severity of illness. No 
signiﬁ cant between group differences were observed for mean length of stay (adherent
49 days, non-adherent 45 days), p  0.12, least squares means (adjusted for CGI-S,
gender and exacerbations) or time to improvement, p  0.31, log-rank test. CONCLU-
SIONS: Use of an optional algorithm for inpatients, designed to improve cost efﬁ ciency
without denying access to non-preferred medications, did not prolong length of stay 
or delay time to desired improvement.
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OBJECTIVES: To assess the impact of the FDA antidepressant Black Box warning on
treatment continuity of antidepressants in children with depression. METHODS: The 
study was a retrospective cohort analysis using 2003–2004 Texas Medicaid claims 
data obtained from Center for Medicare and Medicaid Services. Study cohort included 
patients who were 1) continuously enrolled for Texas Medicaid from January 2003 
to December 2004; 2) at age of 6 to 18; 3) receiving at least two outpatient diagnoses 
with depressive disorders (ICD9-CM codes: 296.xx, 293.xx, 298.xx, 300.xx, 301.xx, 
309.xx, 311.xx) and 4) using Selective Serotonin Re-uptake Inhibitors (SSRIs) pre-
scriptions. Initiation of SSRI therapy was deﬁ ned as ﬁ rst prescription ﬁ ll during
January 1, 2003-January 30, 2003 for the pre-policy cohort and January 1, 2004 – 
January 30, 2004 for the policy cohort. Both cohorts were followed till the end of the
year to observe treatment discontinuation. The discontinuation of SSRI treatment was
deﬁ ned as a gap of 30 days or more between prescriptions. Cox proportional hazard
model was applied to examine the risk of treatment discontinuity due to FDA public
advisory on antidepressants in March 2004. RESULTS: A total of 7184 children 
who met all inclusive criteria were identiﬁ ed, out of which 3367 were in pre-policy 
cohort and 3817 were in policy cohort. Mean age of cohort was 13.75 (SD  3.81). 
The average during pre-policy and policy period were 61.83 days and 55.65 days
respectively. After FDA issued the public advisory on antidepressant in March 2004, 
the risk of antidepressant discontinuation did not change (HR  1.148, 95% CI 
0.907–1.453, p-value  0.2945) compared to the pre-policy period after controlling
patient demographics. CONCLUSIONS: The FDA public advisory on antidepressants 
was not associated with increased risk of SSRI antidepressant treatment discontinua-
tion. Further study is warranted to assess the long term effects of the Black box 
warning on the use of antidepressants.
